Key result
Dyslipidemia is linked to ~37.9-fold higher odds of pre-STEMI primary prevention statin use.
Why the study?
The study aimed to determine the utilization rate of statin therapy for primary prevention of cardiovascular disease and factors associated with its use prior to a first STEMI.
What is the utilization rate and what are the predictors of statin therapy for primary prevention of CVD in patients prior to experiencing their first STEMI?
Cohort (n=177)
No
What is the utilization rate and what are the predictors of statin therapy for primary prevention of CVD in patients prior to experiencing their first STEMI?
Odds Ratio: 37.9 (95% CI 6.716–213.87)
p-value: p=<0.001
Statin therapy for primary prevention remains significantly underutilized in Malaysian patients prior to developing a first STEMI, underscoring a gap in clinical guideline adherence.
Statin underutilization before first STEMI highlights prevention gaps; leaves open whether targeting dyslipidemia improves primary prevention uptake.
Background and Aims: This retrospective cohort study aimed to determine the utilization rate of statin therapy for primary prevention of cardiovascular disease (CVD) and factors associated with its use in patients prior to experiencing their first ST-elevation myocardial infarction (STEMI). Methods: The study included 177 patients admitted for their first episode of STEMI at a Malaysian secondary hospital in 2020. Data were retrospectively collected from the electronic health information system. Logistic regression analysis was performed to identify significant predictors of statin therapy utilization for primary prevention. Results: = 28) had been prescribed statin therapy for the primary prevention of CVD prior to their first STEMI. Hypertension and dyslipidemia were identified as significant predictors of statin use, with adjusted odds ratios (AOR) of 9.570 (95% CI: 1.859-49.281) and 37.900 (95% CI: 6.716-213.87), respectively. Follow-up data indicated significantly reduced cholesterol levels post-STEMI, demonstrating the lipid-lowering effectiveness of statin therapy. Conclusion: This study highlights the low utilization rate of statin therapy for primary prevention of CVD among patients prior to their first STEMI. Despite the proven effectiveness of statins in lowering cholesterol levels post-STEMI, there is a need to enhance awareness, adherence to guidelines, and efforts to achieve LDL-C targets through appropriate statin therapy.
No takes yet. Share an insight, caveat, or question.
Zaihan et al. (2025) conducted a cohort in First ST-elevation myocardial infarction (STEMI) (n=177). Statin therapy prior to STEMI vs. No prior statin therapy was evaluated on Dyslipidemia as a predictor of statin therapy utilization for primary prevention (AOR 37.900, 95% CI 6.716-213.87, p=<0.001). Only 15.8% of patients received statin therapy prior to their first STEMI, with dyslipidemia acting as the strongest significant predictor of prior statin use (AOR 37.90).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: